Fluoguide AS
STO:FLUO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
33.9
75.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Fluoguide AS
Total Current Liabilities
Fluoguide AS
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F
|
Fluoguide AS
STO:FLUO
|
Total Current Liabilities
kr16.3m
|
CAGR 3-Years
10%
|
CAGR 5-Years
199%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Total Current Liabilities
kr4.4B
|
CAGR 3-Years
48%
|
CAGR 5-Years
53%
|
CAGR 10-Years
19%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Total Current Liabilities
kr245.6m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
19%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Total Current Liabilities
€838.5m
|
CAGR 3-Years
93%
|
CAGR 5-Years
82%
|
CAGR 10-Years
51%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Total Current Liabilities
kr3.6B
|
CAGR 3-Years
26%
|
CAGR 5-Years
73%
|
CAGR 10-Years
31%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Total Current Liabilities
kr23.2m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
12%
|
CAGR 10-Years
9%
|
|
Fluoguide AS
Glance View
FluoGuide A/S engages in the development of surgical solutions to reduce suffering for the patient and increase the likelihood of cure; as well as reducing costs for the health care system. The firm develops surgical solutions, which expected to reduce Cancer pain for the patient and increases the possibility of recovering as well as reducing costs for the health care system. The first product is the compound FG001, which lights up the cancer and its invasive growth into the surrounding tissue.
See Also
What is Fluoguide AS's Total Current Liabilities?
Total Current Liabilities
16.3m
DKK
Based on the financial report for Dec 31, 2023, Fluoguide AS's Total Current Liabilities amounts to 16.3m DKK.
What is Fluoguide AS's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
199%
Over the last year, the Total Current Liabilities growth was 345%. The average annual Total Current Liabilities growth rates for Fluoguide AS have been 10% over the past three years , 199% over the past five years .
You don't have any saved screeners yet
